MedTrace Logo

MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)

NCT00420420 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2015-02-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the efficacy and safety of an investigational medication for improving symptoms of Alzheimer's Disease. Subjects will receive either active medication or placebo for 28 days. Tests of memory, concentration will be included. Safety will be monitored using routine clinical and laboratory tests.

Conditions

Interventions

DRUG

MK0249

MK0249 two (2) 2.5 mg capsules quaque die (qd) for 28 day treatment period.

DRUG

Comparator: Placebo (unspecified)

MK0249 two (2) 2.5 mg Pbo capsules qd for a 28 day treatment period

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-08-31
Completion
2008-08-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00420420 on ClinicalTrials.gov